Dr Esteva on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Related Keywords

Franciscoj Esteva ,Palbociclib Ibrance ,Division Of Hematology Oncology ,Northwell Health ,Breast Medical Oncology ,Lenox Hill Hospital ,Science Summit ,Breast Cancer ,Onclive Tv ,